Pasatru First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva 19 August
